Human Genome Epidemiology Literature Finder
Records 1 - 10 (of 10 Records) |
Query Trace: Colorectal Neoplasms and UGT1A9[original query] |
---|
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Feb 11 (3): 1226-36. Carlini Leslie E, Meropol Neal J, Bever John, Andria Michael L, Hill Todd, Gold Philip, Rogatko Andre, Wang Hao, Blanchard Rebecca |
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 May 27 (15): 2457-65. Cecchin Erika, Innocenti Federico, D'Andrea Mario, Corona Giuseppe, De Mattia Elena, Biason Paola, Buonadonna Angela, Toffoli Giusep |
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. British journal of cancer 2010 Aug 103 (4): 581-9. Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano J L, Moreno |
Polymorphisms in heterocyclic aromatic amines metabolism-related genes are associated with colorectal adenoma risk. International journal of molecular epidemiology and genetics 2012 3 (2): 96-106. Eichholzer Monika, Rohrmann Sabine, Barbir Aline, Hermann Silke, Teucher Birgit, Kaaks Rudolf, Linseisen Jak |
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer science 2013 Dec 104 (12): 1662-9. Hazama Shoichi, Mishima Hideyuki, Tsunedomi Ryouichi, Okuyama Yusuke, Kato Takeshi, Takahashi Ken-ichi, Nozawa Hiroshi, Ando Hideaki, Kobayashi Michiya, Takemoto Hiroyoshi, Nagata Naoki, Kanekiyo Shinsuke, Inoue Yuka, Hamamoto Yoshihiko, Fujita Yusuke, Hinoda Yuji, Okayama Naoko, Oba Koji, Sakamoto Jun-ichi, Oka Masaa |
A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes. International journal of oncology 2014 Oct 45 (4): 1381-90. Tsunedomi Ryouichi, Hazama Shoichi, Fujita Yusuke, Okayama Naoko, Kanekiyo Shinsuke, Inoue Yuka, Yoshino Shigefumi, Yamasaki Takahiro, Suehiro Yutaka, Oba Koji, Mishima Hideyuki, Sakamoto Junichi, Hamamoto Yoshihiko, Oka Masaa |
XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer. Oncology letters 2014 Oct 8 (4): 1864-1872. Cui Chengxu, Shu Chang, Yang Yi, Liu Junbao, Shi Shuping, Shao Zhujun, Wang Nan, Yang Ting, Hu Songni |
Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC cancer 2017 Jun 17 (1): 437. Liu Dan, Li Jian, Gao Jing, Li Yanyan, Yang Rui, Shen L |
Effect of UGT, SLCO, ABCB and ABCC polymorphisms on irinotecan toxicity. Medicina clinica 2018 Feb . García Gil Sara, Ramos Díaz Ruth, Nazco Casariego Gloria Julia, Llanos Muñoz Marta, Viña Romero Maria Micaela, Martín Calero Braulio, Pérez Pérez Jose Antonio, Gutiérrez Nicolás Fernan |
Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers. Cancer chemotherapy and pharmacology 2021 2 87 (6): 767-777. Kobayashi Kazuo, Sugiyama Erika, Shinozaki Eiji, Wakatsuki Takeru, Tajima Masataka, Kidokoro Hiyori, Aoyama Takeshi, Nakano Yasuhiro, Kawakami Kazuyoshi, Hashimoto Koki, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Chin Keisho, Nakayama Izuma, Ooki Akira, Takahari Daisuke, Suzuki Wataru, Yokokawa Takashi, Minowa Yuichi, Hiraoka Tomoko, Suzuki Kenichi, Sato Hitoshi, Hama Toshihiro, Yamaguchi Kens |
- Page last reviewed:Feb 1, 2024
- Content source: